| Oct 8 |
Immunome Appoints Roee Shahar as Executive Vice President, Commercial
|
| Oct 8 |
Immunome Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
|
| Sep 13 |
Immunome to Present Updated Results for RINGSIDE Phase 2 Trial of AL102 for the Treatment of Desmoid Tumors at the European Society for Medical Oncology (ESMO) Congress 2024
|
| Aug 20 |
Immunome Stock Sees RS Rating Jump To 91
|
| Aug 14 |
Immunome Second Quarter 2024 Earnings: Revenues Beat Expectations, EPS Lags
|
| Aug 13 |
Immunome GAAP EPS of -$0.60 misses by $0.17, revenue of $2.37M beats by $0.5M
|
| Aug 12 |
Immunome, Inc. (IMNM) Reports Q2 Loss, Misses Revenue Estimates
|
| Aug 12 |
Immunome Reports Second Quarter 2024 Financial Results and Provides Business Update
|
| Jul 25 |
Immunome Provides Update on Recent Business Development Activity Expected to Expand ADC Capabilities
|
| Jul 19 |
Immunome Insiders Added US$2.67m Of Stock To Their Holdings
|
